Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by 1ST Source Bank

1ST Source Bank boosted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,658 shares of the medical equipment provider’s stock after acquiring an additional 27 shares during the quarter. 1ST Source Bank’s holdings in Intuitive Surgical were worth $5,186,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Intuitive Surgical by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after acquiring an additional 493,126 shares during the period. Price T Rowe Associates Inc. MD increased its position in Intuitive Surgical by 1.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after acquiring an additional 272,741 shares during the period. Capital World Investors increased its position in Intuitive Surgical by 1.0% in the 1st quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after acquiring an additional 73,634 shares during the period. Edgewood Management LLC increased its position in Intuitive Surgical by 7.9% in the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after acquiring an additional 374,667 shares during the period. Finally, Jennison Associates LLC increased its position in Intuitive Surgical by 4.6% in the 1st quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock valued at $1,791,253,000 after acquiring an additional 198,483 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Robert Desantis sold 188 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total transaction of $90,655.48. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at $2,655,048.26. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the transaction, the director now directly owns 12,275 shares in the company, valued at $5,441,507.50. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Robert Desantis sold 188 shares of the firm’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,655,048.26. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,555 shares of company stock worth $24,267,737. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Down 0.8 %

Shares of Intuitive Surgical stock opened at $489.86 on Friday. The stock has a market cap of $173.75 billion, a PE ratio of 88.42, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39. The business has a fifty day simple moving average of $463.74 and a 200-day simple moving average of $421.55. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. Intuitive Surgical’s revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.18 earnings per share. Analysts expect that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their price target on Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. BTIG Research lifted their price target on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and lifted their price target for the company from $380.00 to $510.00 in a research report on Friday, August 2nd. Citigroup lifted their price target on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Finally, Truist Financial lifted their price target on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $446.45.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.